Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma

Maxime Fayon; Carolina Martinez-Cingolani; Audrey Abecassis; Nathalie Roders; Elisabeth Nelson; Caroline Choisy; Alexis Talbot; Armand Bensussan; Jean-Paul Fermand; Bertrand Arnulf; Jean-Christophe Bories

doi:10.3324/haematol.2019.242453

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma

Haematologica. 2021 Apr 1;106(4):1193-1197. doi: 10.3324/haematol.2019.242453.

Affiliations

¹ Institut de recherche Saint-Louis, Inserm U976.
² Institut de recherche Saint-Louis, InsermU976.
³ Immunology-Haematology department, Hôpital Saint-Louis, AP-HP.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bispecific*
CD3 Complex
Humans
Multiple Myeloma* / drug therapy
T-Lymphocytes

Substances

Antibodies, Bispecific
CD3 Complex

Grants and funding

Funding: this work was supported by grants from the “Cancéropole Ile de France” and from the “Fondation Française pour la Recherche contre le Myélome et les Gammapathies monoclonales”. MF and CM-C were supported by fellowships from the French “Agence National pour la Recherche”, programme d’Investissements d’avenir (ANR-10-IDEX-03-02). MF was also supported by a fellowship from the “Société Française d’Hématologie”. AA was supported by a fellowship from the “Agence Nationale pour la Recherche Scientifique, CIFRE” in partnership with Servier.